NCT00337467

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose is to explore whether atazanavir/ritonavir (ATV/RTV) single enhanced protease inhibitor therapy can maintain virologic suppression without a marked increase in virologic failure.

Conditions

• Human Immunodeficiency Virus (HIV) Infections

Interventions

Type	Name	Description
DRUG	Atazanavir + Ritonavir	Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks

Timeline

• Start date: 2006-06-01
• Primary completion: 2008-05-01
• Completion: 2009-05-01
• First posted: 2006-06-16
• Last updated: 2010-07-19
• Results posted: 2010-07-19

Locations

7 sites across 1 country: Spain